Octinoxate

Octinoxate

SCHEMBL29435124

CCCCC(CC)COC(=O)C=Cc1ccc(OC)cc1.CCCCCCCCC(=Cc1ccc(OC)cc1)C(=O)O

nearest known ligand 0.76

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.76
TAS1R3 Q7RTX0 4/20 0.46
TAS1R1 Q7RTX1 4/20 0.46
LMNA P02545 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.44
TSHR P16473 2/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
CYP3A4 P08684 2/20 0.40
GAA P10253 1/20 0.40
PRSS1 P07477 1/20 0.40
PRSS2 P07478 1/20 0.40
PRSS3 P35030 1/20 0.40
ATM Q13315 1/20 0.40
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
ALOX5 P09917 1/20 0.39
FFAR1 O14842 1/20 0.39
PPARG P37231 1/20 0.39
PPARD Q03181 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Octinoxate SCHEMBL30081040 0.91 TDP1 (0.79) TDP1TAS1R3TAS1R1LMNASMN1; SMN2
SCHEMBL1960360 0.87 TDP1 (0.91) TDP1TAS1R3TAS1R1LMNASMN1; SMN2
SCHEMBL9098850 0.87 TDP1 (0.91) TDP1TAS1R3TAS1R1LMNASMN1; SMN2
SCHEMBL9098855 0.87 TDP1 (0.91) TDP1TAS1R3TAS1R1LMNASMN1; SMN2
SCHEMBL1960361 0.87 TDP1 (0.91) TDP1TAS1R3TAS1R1LMNASMN1; SMN2
Octinoxate SCHEMBL15609 0.87 TDP1 (1.00) TDP1TAS1R3TAS1R1LMNASMN1; SMN2
Octinoxate SCHEMBL15803545 0.87 TDP1 (1.00) TDP1TAS1R3TAS1R1LMNASMN1; SMN2
Octinoxate SCHEMBL30252195 0.87 TDP1 (1.00) TDP1TAS1R3TAS1R1LMNASMN1; SMN2
Octinoxate SCHEMBL39360 0.87 TDP1 (1.00) TDP1TAS1R3TAS1R1LMNASMN1; SMN2
Octinoxate SCHEMBL1768913 0.87 TDP1 (1.00) TDP1TAS1R3TAS1R1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024171519-A1 CHOLESTERIC LIQUID CRYSTAL COMPOSITION 日本精化株式会社 2024-08-22 WO disclosed
US-20230404888-A1 COMPOSITION CONTAINING LIPID PEPTIDE AND SUCROSE ESTER NISSAN CHEMICAL CORPORATION (JP) 2023-12-21 US disclosed
US-11771645-B2 Transdermally absorbable base material containing lipid peptide compound KYUSHU UNIVERSITY (JP) 2023-10-03 US disclosed
EP-4230265-A1 COMPOSITION CONTAINING LIPID PEPTIDE AND SUCROSE ESTER Nissan Chemical Corporation (JP) 2023-08-23 EP disclosed
EP-3251656-B1 MOISTURIZING BASE MATERIAL INCLUDING LIPID-PEPTIDE COMPOUND UNIV KYUSHU (JP) 2023-07-05 EP disclosed
CN-113015515-B Cosmetic product 日本精化株式会社 2023-06-09 CN disclosed
US-20230062111-A1 ANTI-POLLUTION MATERIAL NISSAN CHEMICAL CORPORATION (JP) 2023-03-02 US disclosed
EP-3881823-B1 SOLID BASE MATERIAL CONTAINING LIPID PEPTIDE COMPOUND NISSAN CHEMICAL CORP (JP) 2023-01-25 EP disclosed
CN-110662528-B Water-in-oil type cosmetic 富士胶片株式会社 2022-12-27 CN disclosed
EP-4074380-A1 ANTI-POLLUTION MATERIAL Nissan Chemical Corporation (JP) 2022-10-19 EP disclosed
US-11452688-B2 Transdermally absorbable base material containing lipid peptide compound KYUSHU UNIVERSITY (JP) 2022-09-27 US disclosed
US-20220251393-A1 PIGMENTS CONTAINING CELLULOSE NISSAN CHEMICAL CORPORATION (JP) 2022-08-11 US disclosed
CN-110769800-B Cosmetic composition containing fullerene 维生素C60生化学研究公司 2022-06-28 CN disclosed
EP-4014958-A1 COATING FILM-FORMING COMPOSITION Nissan Chemical Corporation (JP) 2022-06-22 EP disclosed
EP-4006110-A1 PIGMENT INCLUDING CELLULOSE Nissan Chemical Corporation (JP) 2022-06-01 EP disclosed
CN-114173752-A Cellulose-containing pigments 日产化学株式会社 2022-03-11 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230404888-A1 COMPOSITION CONTAINING LIPID PEPTIDE AND SUCROSE ESTER CUTA, SCAMP3, SURF4 TDP1 2861/4885TAS1R3 1374/4885TAS1R1 1928/4885
US-20230062111-A1 ANTI-POLLUTION MATERIAL PLIN3, CUTA, PLIN5 TDP1 3230/4885TAS1R3 2845/4885TAS1R1 3641/4885
US-11771645-B2 Transdermally absorbable base material containing lipid peptide compound NGLY1, NR1H4, HRH1 TDP1 2842/4885TAS1R3 999/4885TAS1R1 628/4885
US-11452688-B2 Transdermally absorbable base material containing lipid peptide compound NGLY1, NR1H4, HRH1 TDP1 2842/4885TAS1R3 999/4885TAS1R1 628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.